

Pharmacy Prior Authorization Form

Fax completed form to: 877.974.4411 toll free, or 616.942.8206

This form applies to: Commercial (Traditional) Commercial (Individual/Optimized)

Medicaid

This request is: Urgent (life threatening) Non-Urgent (standard review)

Urgent means the standard review time may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.

Neupogen[®] (filgrastim)

Member

Last Name: _____ First Name: _____

ID #: _____ DOB: _____ Gender: _____

Primary Care Physician: _____

Requesting Provider: _____ Prov. Phone: _____ Prov. Fax: _____

Provider Address: _____

Provider NPI: _____ Contact Name: _____

Provider Signature: _____ Date: _____

Product Information

New request Continuation request

Drug product: Neupogen 300 mcg/0.5mL syringe
 Neupogen 300 mcg/mL vial
 Neupogen 480 mcg/0.8mL syringe
 Neupogen 480 mcg/1.6mL vial

Start date (or date of next dose): _____
 Date of last dose (if applicable): _____
 Dosing frequency: _____

Precertification Requirements

Before this drug is covered, the patient must meet all of the following requirements:

1. Must be prescribed by a hematologist and/or oncologist, or other specialist per associated diagnosis/indication
2. Must provide medical records documenting indication and absolute neutrophil count (ANC)
3. Using for chemotherapy-induced neutropenia and meet the following:
 - Must have a non-myeloid malignancy
 - Chemotherapy regimen is identified as having a high overall risk ($\geq 20\%$) of febrile neutropenia
 - OR**
 - Chemotherapy regimen is identified as having an intermediate overall risk (10%-20%) of febrile neutropenia **AND** patient is at high-risk for neutropenic complications (e.g., age > 65, pre-existing neutropenia or tumor involvement in the bone marrow, infection, renal or liver impairment, other serious co-morbidities) **OR** patient experienced a neutropenic complication from a prior cycle of the same chemotherapeutic regimen
 - Neupogen is administered 24 – 72 hours after completion of chemotherapy
 - Patient is not receiving concurrent chemotherapy and radiation therapy
 - Must have first tried and failed or have a contraindication to Granix AND Zarxio
 - Up to a 14-day supply will be approved per cycle of chemotherapy (can include refills if number of cycles of chemotherapy is included in the request)

4. Using for treatment of neutropenia and meet the following:
 - Severe chronic congenital neutropenia, cyclic neutropenia, idiopathic neutropenia, use for myeloid reconstitution after bone marrow transplant (must have a non-myeloid cancer), use following reinfusion of peripheral blood stem cells, OR drug-induced neutropenia in immunosuppressed patients that meets *one* of the following:
 - i. Evidence of inadequate bone marrow reserve (e.g., recurrent fevers, splenomegaly, mucosal ulcers, abdominal pain)
 - ii. High risk for the development of serious bacterial infections (e.g., primarily severe neutropenia, indwelling venous catheters, prior serious infections)
 - iii. Documented bacterial infection
 - Must have first tried and failed or have a contraindication to Zarxio
 - Approval can be granted for 3 months
5. Using for peripheral blood stem cell mobilization in cancer patients preparing to undergo bone marrow ablation.
 - Must have first tried and failed or have a contraindication to Zarxio
6. Using for acute radiation exposure (following myelosuppressive doses of radiation at a dose of 2gray [GY])
 - Must have first tried and failed or have a contraindication to Zarxio

For continuation, patient must have met the following requirements:

1. Using for chemotherapy-induced neutropenia:
 - Must have a recent ANC showing a response to therapy
 - Up to a 14 day supply will be approved per cycle of chemotherapy, can include refills if number of cycles of chemotherapy is included in request
2. All other indications (e.g., neutropenia, peripheral blood stem cell mobilization, acute radiation exposure):
 - Must have a recent ANC showing a response to therapy
 - Approval will be for 30 days

NOTE: Therapy may be discontinued if patient is noncompliant with medical or pharmacologic therapy OR no demonstrable clinically significant improvement in condition has occurred after initiation of drug therapy.

Note: Authorization for indications, dosing, or a route of administration not approved by the Food and Drug Administration (FDA) or recognized in CMS-accepted compendia (e.g. DrugDex, AHFS, U.S. Pharmacopeia, and also Clinical Pharmacology for oncology indications only) require supporting evidence for coverage. Please provide two published peer-reviewed literature articles supporting the appropriateness of the drug, the dosing of the drug, or the route of administration to be used for the identified indication.

New request
Priority Health Precertification Documentation

A. Is the prescribing doctor a hematologist and/or oncologist, or other specialist per associated diagnosis/indication?

- Yes
 No

B. Has an absolute neutrophil count (ANC) been provided?

- Yes (Please fax results to Priority Health)
 No. *Rationale for use:* _____

C. What condition is this drug being requested for?

- Chemotherapy-induced neutropenia

1. Has the patient tried Granix?

- Yes
 No. *Rationale for use:* _____

2. Does the patient have a non-myeloid malignancy?

- Yes
 No. *Rationale for use:* _____

3. Please list the chemotherapy regimen Neupogen will be used with:

Drug Names:	Dose:	Cycle Dates:
Drug 1 _____	_____	_____
Drug 2 _____	_____	_____
Drug 3 _____	_____	_____
Drug 4 _____	_____	_____

4. Please indicate if the patient's chemotherapy regimen has a high (>20%) or intermediate risk (10%-20%) of chemotherapy-induced neutropenia:

- High risk (>20%)
- Intermediate risk (10%-20%)

5. For patient's using an intermediate risk chemotherapy regimen, is the patient at high-risk for neutropenic complications?

- Yes

If yes, check all risk factors that apply to the patient:

- Age >65
- Pre-existing neutropenia
- Tumor involvement in the bone marrow
- Infection
- Renal impairment
- Liver impairment
- Other serious co-morbidities: _____

- No. *Rationale for use:* _____

6. For patient's using an intermediate risk chemotherapy regimen, has the patient experienced a neutropenic complication from a prior cycle of the same chemotherapeutic regimen?

- Yes
- No

7. Is Neupogen being administered 24-72 hours after completion of chemotherapy?

- Yes
- No. *Rationale for use:* _____

8. Is patient receiving chemotherapy and radiation at the same time as Neupogen use?

- Yes. *Rationale for use:* _____
- No

- Severe chronic neutropenia, cyclic neutropenia, or idiopathic neutropenia
- Drug induced neutropenia in immunosuppressed patients

1. Which of the following applies?

- Evidence of inadequate bone marrow reserve (e.g., recurrent fevers, splenomegaly, mucosal ulcers, abdominal pain)
- High risk for the development of serious bacterial infections (e.g., primarily severe neutropenia, indwelling venous catheters, prior serious infections)
- Documented bacterial infection

- Myeloid reconstitution after autologous or allogenic bone marrow transplant
- Following reinfusion of peripheral blood stem cells
- Peripheral blood stem cell mobilization
- Acute radiation exposure
- Other – the patient's condition is: _____

Rationale for use: _____

D. Has the patient used Zarxio?

- Yes
- No, Rationale for use: _____

**Continuation request
Priority Health Precertification Documentation**

A. What condition is this drug being requested for?

- Chemotherapy-induced neutropenia
 - Severe chronic neutropenia, cyclic neutropenia, or idiopathic neutropenia
 - Drug induced neutropenia in immunosuppressed patients
 - Myeloid reconstitution after autologous or allogenic bone marrow transplant
 - Following reinfusion of peripheral blood stem cells
 - Peripheral blood stem cell mobilization
 - Acute radiation exposure
 - Other – the patient’s condition is:* _____
- Rationale for use:* _____

B. Has a recent absolute neutrophil count (ANC) been provided?

- Yes
- No, Rationale for use: _____

C. Does the recent ANC support a clinical response to the use of Neupogen?

- Yes
- No, Rationale for use: _____